Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Biogen’s Aduhelm Price Cut Prompts Medicare Premium Review (1)

Jan. 10, 2022, 5:50 PM

Biogen Inc.’s decision last month to cut the price of its Alzheimer’s drug in half prompted the top U.S. health official to order a review of Medicare premium hikes tied to the drug.

Health and Human Services Secretary Xavier Becerra instructed the Centers for Medicare & Medicaid Services to reassess the planned member premium increases for 2022 Medicare coverage, according to a statement Monday.

The high price of Aduhelm -- initially $56,000 a year -- combined with uncertainty over how many patients might take it drove large increases in Medicare premiums this year. About half of the annual increase ...